We are a vertically integrated company that develops, manufactures and markets Generic, Branded Generic, Value-added and Over-the-Counter (OTC) products, Anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates. We have a large portfolio of over 500 molecules that cover multiple dosage forms including tablets, capsules, injectables, inhalers, ointments, creams and liquids. Our presence extends across therapies and includes Anti-infectives, Cardiovascular, Pain management, Central Nervous System (CNS), Gastrointestinal, Respiratory, Dermatology, Orthopaedics, Nutritionals and Urology. Biotech and Vaccines are two new segments that we have begun investing in. A stronger presence in these areas will add significant depth to the existing product pipeline.
Through our unique hybrid business model involving Daiichi Sankyo, we also introduce innovator products in markets around the world.
Our continued focus on Research & Development (R&D) has resulted in several regulatory approvals in both developed and emerging markets. We have multiple R&D centres in Gurgaon, Haryana, India with facilities for generic and innovative research. The product SynriamTM, is a new age cure for Malaria. With a strong focus on research in generics, we are increasingly working on more complex and specialised areas.
Our business philosophy, based on delivering value to our stakeholders, constantly inspires our people to innovate, excel and set new global benchmarks. Our multicultural workforce, comprising more than 14,000 employees of over 50 nationalities, gives us the strength to make quality healthcare accessible to people around the world. We remain committed to aggressively pursuing our mission of 'Enriching lives globally, with quality and affordable pharmaceuticals'.